Paper
0
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Authors
Joseph Fraietta,Kyle Beckwith
Prachi Patel,Marco Ruella,Zhaohui Zheng,David Barrett,Simon Lacey,J. Melenhorst,Shannon McGettigan,Danielle Cook,Changfeng Zhang,Jun Xu,Priscilla Do,Jessica Hulitt,Sagar Kudchodkar,Alexandria Cogdill,Saar Gill,David Porter,Jennifer Woyach,Meixiao Long,Amy Johnson,Kami Maddocks,Natarajan Muthusamy,Bruce Levine,Carl June,John Byrd
+24 authors
,Marcela MausJournal
Published
Jan 27, 2016
Show more
Save
Tip0
TipSave
Abstract
Key Points Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.